Takeda Publishes the Results of Takhzyro (lanadelumab) in P-III HELP Study for the Prevention of Hereditary Angioedema Attacks in the Journal Allergy

August 6, 2021 Auto Bot allergy, Clinical Trials, P-III, Takeda 0

Shots:

  • The P-III HELP OLE study evaluates the safety & efficacy of Takhzyro (300mg, q2w) in 212 patients aged ≥12yrs. with HAE attacks for ~2.5yrs.
  • Results: 87.4% mean reduction in attack rate compared to baseline; attacks requiring acute treatment (93.4%); mod. or sev. attacks (84.3%); HAE attack-free (97.7%) with a duration of the attack-free period (14.8mos.), 68.9% experienced an attack-free period of 12+ mos.
  • Additionally, the safety profile was consistent with the original findings from the HELP Study with TEAEs occurring in 54.7% of patients. Takhzyro is a mAb targeting plasma kallikrein activity, indicated for HAE attacks in patients aged ≥12 yrs.

Click here to­ read full press release/ article | Ref: Takeda | Image: The Japan Times

The post Takeda Publishes the Results of Takhzyro (lanadelumab) in P-III HELP Study for the Prevention of Hereditary Angioedema Attacks in the Journal Allergy first appeared on PharmaShots.